Video

Dr. Black on Combinations with Durvalumab in Bladder Cancer

Author(s):

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Durvalumab works as a monotherapy for the second-line setting after cisplatin therapy, explains Black. In the first-line setting there is a combination trial of durvalumab versus durvalumab plus tremelimumab versus standard chemotherapy.

In other disease sites, the combination works well—making people very optimistic but the results will take a few years, states Black.

Related Videos
Drs Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD